Search

One year ago on April 14, 2023, I was honored to stand by Gov. Ron DeSantis as he signed the 6 week bill also known as 'The Heartbeat Bill'. This [...]

UPDATE: We are deeply encouraged and thank you for your response to this critical campaign! Please continue to educate ... send this flyer to as many Floridians as possible. Florida [...]

Four short years ago, Ron DeSantis, candidate for Florida's Governor, won his race in a super tight election. He eked out a victory by a mere 32,000 votes out of [...]

This year, in the 2018 midterms, pro-abortion Democrats were salivating at the possibility of gaining congressional seats across the nation. A typical midterm election customarily results in losses for the [...]

The article reports on the ruling by the Florida First District Court of Appeals on July 25, 2024 that the financial impact statement dealing with Amendment 4 is appropriate and will stand as written. Topics discussed include ruling of Circuit judge John Cooper on June 10 on the outdated information in the financial impact statement, consequence if 60 percent of Floridians vote in favor of Amendment 4, and statement from the Florida Right to Life.

Editor's note. This month's guest presidential column is written by Lynda Bell, president of Florida Right to Life and chairman of the National Right to Life Board of Directors. On [...]

The article offers the author's insights on the resources available for searching U.S. or Canadian bricklayer ancestors such as the use of the International Union (IU) registration number to identify and trace ancestor in IU and local records.

A single, recurrent somatic point mutation (402C→G) in FOXL2has been described in almost all adult-type granulosa cell tumors but not other ovarian neoplasms. Histopathological features of adult-type granulosa cell tumors can be mimicked by a variety of other tumors, making diagnosis of adult-type granulosa cell tumor challenging. It has been suggested that molecular testing for FOXL2mutation might be a useful tool in the diagnosis of adult-type granulosa cell tumors. The aim of this study was to demonstrate how testing for the FOXL2mutation can be used in a gynecological pathology consultation service and to establish clear procedural guidelines for FOXL2testing. Immunohistochemistry for FOXL2 was done using an anti-FOXL2 polyclonal antiserum. If immunohistochemistry was positive, FOXL2mutation status was subsequently analyzed using a TaqMan assay. A dilution experiment was done to assess the sensitivity and minimum tumor cellularity requirements for our TaqMan assay. Twenty problematic cases were assessed, where the differential diagnosis after the initial investigations included adult-type granulosa cell tumors. Differential diagnoses included: thecoma, Sertoli–Leydig cell tumor, juvenile granulosa cell tumor, endometrial stromal sarcoma and others. In all cases, FOXL2 immunohistochemistry was positive and in six samples the FOXL2mutation was detected, thus confirming a diagnosis of adult-type granulosa cell tumor. The TaqMan assay was able to reliably detect the FOXL2mutation with input DNA in the range of 2.5–20 ng, and with a minimum of 25% tumor cell nuclei. The analysis of the FOXL2mutational status in clinical samples is a useful diagnostic tool in situations where the differential diagnosis is between adult-type granulosa cell tumor and other ovarian tumors. The TaqMan assay requires a minimum of 2.5 ng DNA, with optimal assay performance for 5 to 10 ng DNA input. Laser capture or needle-macrodissection should be undertaken to enrich samples with tumor cell content below 25%.

The article relates the author's experience of dealing with the pregnancy of a teenage daughter. The author and her husband decided to allow their daughter and her boyfriend to get married because putting him in jail would mean losing their daughter. The author recalls how her daughter called for her during delivery. When the time came for her daughter to go to Hawaii with her husband, she requested for the flight attendant to watch out for her and the baby.